Navigation Links
Amicus Therapeutics Announces Third Quarter 2007 Financial Results
Date:10/31/2007

P basis, general and administrative expense for the three months ended September 30, 2007, was $3.3 million, a decrease of $0.1 million from $3.4 million from the three months ended September 30, 2006.

The differences between U.S. GAAP EPS, net loss, research and development expense and general and administrative expense and the corresponding non-GAAP amounts are itemized in table 2 and 3, and are primarily due to:

-- Pre-tax share-based compensation expense under SFAS No. 123R of $1.1

million (or $0.05 per share) for the three months ended September 30,

2007, primarily related to employee stock option expense.

-- Pre-tax charges for preferred stock accretion.

-- Pre-tax charges for changes in the fair value of warrant liability.

Use of Non-GAAP Financial Measures

Our "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding, for the reasons discussed below,

(1) Stock option expense and the cumulative effect of an accounting

change relating to the initial adoption of SFAS No. 123R and (2)

other items. Our management uses these non-GAAP financial measures to

establish financial goals and to gain an understanding of the

comparative financial performance of the Company from year to year

and quarter to quarter. Accordingly, we believe investors'

understanding of the Company's financial performance is enhanced as a

result of our disclosing these non-GAAP financial measures. Non-GAAP

net loss and diluted net loss per common share should not be viewed

in isolation or as a substitute for reported, or GAAP net loss and

diluted net loss per common share.

(2) Stock option expense - Non-GAAP net loss and diluted net loss per

common share exclude the impact of our stock op
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... 2014 Culot brings life science ... management services  BioData, producer of Labguru, the ... announce the appointment of Louis Culot as ... VP Marketing and Business Development at BioDiscovery Inc., developer ... applications. Previously, Culot worked for 17 years ...
(Date:9/1/2014)... The Collaborative R&D Terms and ... comprehensive understanding and unprecedented access to the collaborative ... worlds leading life science companies. , The report ... and why companies enter collaborative R&D deals. , ... deals terms provides critical insight into the negotiation ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4
... Switzerland, October 5, 2011 Debiopharm Group™ ... on drug development and companion diagnostics, today presented the ... Cancer Center Research Institute in Tokyo, for his basic ... genes, and to Doctor Mineo Kurokawa from the University ...
... 4, 2011 The VENTANA anti-Helicobacter pylori (SP48) Rabbit ... H. pylori antibody to receive 510(k) ... by Ventana Medical Systems, Inc. (Ventana), a member of ... used in immunohistochemical (IHC) staining, aids in the detection ...
... JACKSONVILLE, Fla., Oct. 4, 2011 MSC Care ... and services to post-discharge and post-injury workers, compensation ... Integrated Healthcare Services, a national company also focused ... unique and comprehensive surgical implant cost management solution, ...
Cached Biology Technology:The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 2The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 3Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 2Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 3MSC to Offer Surgical Implant Cost Management Solution through Acquisition of Integrated Healthcare Services 2
(Date:9/2/2014)... From AGU,s blogs: Earthquake rupture through a U.S. suburb ... University of California Davis in the hours and days ... helping scientists understand why the earthquake caused so much ... The Trembling Earth blog, hosted by the American Geophysical ... Future Mars Rovers: The Next Places to Direct Our ...
(Date:9/2/2014)... September 3, The Field Museum will present the prestigious ... of his commitment to biodiversity conservation awareness. The Parker/Gentry ... an outstanding individual, team or organization whose efforts have ... natural heritage and whose actions can serve as a ... of Mongabay.com, an environmental science and conservation news website ...
(Date:9/2/2014)... Konservat-Lagersttte of lithographic limestone is well known as ... from that area (for example, Archaeopteryx). Now, for ... in the French equivalent of these outcrops - ... oldest known water treader. , Despite the abundance ... fossils have been obtained from the Late Kimmeridgian ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... to support the theory that old cells help make ... that as these animals age, the number of aging ... cells lose their ability to divide, a state known ... advanced online edition of Science, is the first to ...
... the journal Genome Research that large segments ... mobile DNA elements called transposons. The locations of ... are enriched in genes crucial for the regulation of ... DNA sequences that have the capacity to move from ...
... SIDS (sudden infant death syndrome) in African Americans can be ... deaths result from a common genetic variation that increases an ... of environmental stress, a research team based at the University ... Journal of Clinical Investigation. , Children with two copies ...
Cached Biology News:Aging cells, aging body: Fresh evidence for a connection 2Where 'jumping genes' fear to tread 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3
biotin-4-fluorescein...
Human IL-17D Affinity Purified Polyclonal Ab...
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: